Patent intelligence · US
US 11642384
Compositions and methods for the treatment of Netherton Syndrome
Compositions and methods for the treatment of Netherton Syndrome
Patent details — US 11642384
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 9, 2023
- Expiration
- May 4, 2043
- Applicant
- Krystal Biotech, Inc.
- Claims
- 7
- CPC classes
- A61K, A61K35/763, A61K38/1748, A61K38/39
Quick answer
US 11642384 (Compositions and methods for the treatment of Netherton Syndrome) is held by Krystal Biotech, Inc.. Status: granted. Granted May 9, 2023. Expires May 4, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Krystal Biotech, Inc.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K35/763, A61K38/1748, A61K38/39, A61K38/57, A61K47/38
More from Krystal Biotech, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12364775
Viral vectors for cancer therapy
granted -
US 12128122
Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic
granted -
US 11918660
Viral vectors for cancer therapy
granted -
US 11865148
Methods of delivering transgenes to the eye
granted -
US 11779660
Viral vectors for cancer therapy
granted -
US 11717547
Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
granted -
US 11185564
Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
granted
Frequently asked questions
What is US patent 11642384?
US 11642384 (Compositions and methods for the treatment of Netherton Syndrome) is held by Krystal Biotech, Inc.. Status: granted. Granted May 9, 2023. Expires May 4, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11642384?
Krystal Biotech, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 11642384 expire?
Our index shows an expiration date of May 4, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.